Adherence to Anti-Osteoporotic Treatment and Clinical Implications after Hip Fracture: A Systematic Review

被引：15

作者：

Dobre, Ramona ^{[1
,2
]}

Niculescu, Dan Alexandru ^{[1
,2
]}

Petca, Razvan-Cosmin ^{[1
,3
]}

Popescu, Razvan-Ionut ^{[1
,3
]}

Petca, Aida ^{[1
,4
]}

Poiana, Catalina ^{[1
,2
]}

机构：

[1] Carol Davila Univ Med & Pharm, Bucharest 050474, Romania

[2] Natl Inst Endocrinol CI Parhon, Dept Endocrinol, Bucharest 011853, Romania

[3] Prof Dr Th Burghele Clin Hosp, Dept Urol, Bucharest 050659, Romania

[4] Elias Univ Hosp, Dept Obstet & Gynecol, Bucharest 011461, Romania

来源：

JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 05期

关键词：

anti-osteoporotic treatment; hip fracture; mortality; re-fracture risk; BONE-MINERAL DENSITY; BISPHOSPHONATE USE; EXCESS MORTALITY; ZOLEDRONIC ACID; RISK; DENOSUMAB; WOMEN; SURVIVAL; METAANALYSIS; ASSOCIATION;

D O I：

10.3390/jpm11050341

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

The role of anti-osteoporotic treatment as part of the secondary prevention after hip fracture in terms of mortality and re-fracture risk has been studied, and the results are promising. Decreased treatment adherence and compliance is a problem that needs to be addressed by healthcare professionals. A systematic review of the literature was performed using the PubMed database with terms that included hip fracture, mortality, second fracture, and specific anti-osteoporotic treatment. We included 28 articles, 21 regarding mortality and 20 re-fracture rates in hip fracture patients. All studies showed lower mortality after hip fracture associated with anti-osteoporotic treatment, mostly bisphosphonate agents. The re-fracture risk is still debatable, since conflicting data were found. Although most of the studies showed notable effects on mortality and re-fracture rates associated with anti-osteoporotic treatment, we still need more data to validate the actual results.

引用

页数：17

共 64 条

[1] The Association of Oral Bisphosphonate Use With Mortality Risk Following a Major Osteoporotic Fracture in the United Kingdom: Population -Based Cohort Study [J].

Abtahi, Shahab ;

Burden, Andrea M. ;

Geusens, Piet ;

van den Bergh, Joop P. ;

van Staa, Tjeerd ;

de Vries, Frank .

JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2020, 21 (06) :811-816

[2] The relation of low levels of bone mineral density with coronary artery calcium and mortality [J].

Ahmadi, N. ;

Mao, S. S. ;

Hajsadeghi, F. ;

Arnold, B. ;

Kiramijyan, S. ;

Gao, Y. ;

Flores, F. ;

Azen, S. ;

Budoff, M. .

OSTEOPOROSIS INTERNATIONAL, 2018, 29 (07) :1609-1616

[3] Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle [J].

Akesson, K. ;

Marsh, D. ;

Mitchell, P. J. ;

McLellan, A. R. ;

Stenmark, J. ;

Pierroz, D. D. ;

Kyer, C. ;

Cooper, C. .

OSTEOPOROSIS INTERNATIONAL, 2013, 24 (08) :2135-2152

[4] Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures [J].

Austin, Matthew ;

Yang, Yu-Ching ;

Vittinghoff, Eric ;

Adami, Silvano ;

Boonen, Steven ;

Bauer, Douglas C. ;

Bianchi, Gerolamo ;

Bolognese, Michael A. ;

Christiansen, Claus ;

Eastell, Richard ;

Grauer, Andreas ;

Hawkins, Federico ;

Kendler, David L. ;

Oliveri, Beatriz ;

McClung, Michael R. ;

Reid, Ian R. ;

Siris, Ethel S. ;

Zanchetta, Jose ;

Zerbini, Cristiano A. F. ;

Libanati, Cesar ;

Cummings, Steven R. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (03) :687-693

[5] Treatment Effects of Bisphosphonates and Denosumab on Survival and Refracture from Real-World Data of Hip-Fractured Patients [J].

Behanova, Martina ;

Reichardt, Berthold ;

Stamm, Tanja A. ;

Zwerina, Jochen ;

Klaushofer, Klaus ;

Kocijan, Roland .

CALCIFIED TISSUE INTERNATIONAL, 2019, 105 (06) :630-641

[6]

Benjamin Biju, 2016, Osteoporos Sarcopenia, V2, P77, DOI 10.1016/j.afos.2016.03.003

[7] Bisphosphonates and mortality: confounding in observational studies? [J].

Bergman, J. ;

Nordstrom, A. ;

Hommel, A. ;

Kivipelto, M. ;

Nordstrom, P. .

OSTEOPOROSIS INTERNATIONAL, 2019, 30 (10) :1973-1982

[8] Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study [J].

Bondo, L. ;

Eiken, P. ;

Abrahamsen, B. .

OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) :245-252

[9] Once-Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture [J].

Boonen, Steven ;

Orwoll, Eric ;

Magaziner, Jay ;

Colon-Emeric, Cathleen S. ;

Adachi, Jonathan D. ;

Bucci-Rechtweg, Christina ;

Haentjens, Patrick ;

Kaufman, Jean-Marc ;

Rizzoli, Rene ;

Vanderschueren, Dirk ;

Claessens, Frank ;

Sermon, An ;

Witvrouw, Richard ;

Milisen, Koen ;

Su, Guoqin ;

Lyles, Kenneth W. .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 (11) :2084-2090

[10] Management of osteoporosis in fracture liaison service associated with long-term adherence to treatment [J].

Boudou, L. ;

Gerbay, B. ;

Chopin, F. ;

Ollagnier, E. ;

Collet, P. ;

Thomas, T. .

OSTEOPOROSIS INTERNATIONAL, 2011, 22 (07) :2099-2106

← 1 2 3 4 5 6 7 →